18/06 Flashcards
cANCA
granulomatosis with polyangitis
pANCA
eosinophilic granulomatosis
Ulcerative colitis (70%)
Primary sclerosing cholangitis (70%)
Anti-GBM disease (25%)
Crohn’s disease (20%)
paradoxical rise in APTT and thrombocytopenia
APS
APS primary prophylaxis
low dose aspirin
APS secondary prophylaxis
initial venous thromboembolic events: lifelong warfarin with a target INR of 2-3
recurrent venous thromboembolic events: lifelong warfarin; if occurred whilst taking warfarin then consider adding low-dose aspirin, increase target INR to 3-4
APS tx of arterial thrombosis
lifelong warfarin target INR 2-3
azathioprine prior test
TPMT test
azathioprine adverse effects
bone marrow suppression
n/v
pancreatitis
> risk of non-melanoma skin cancer
but safe in preg !!
azathioprine drug interaction
allopurinol so lower doses needed
oral ulcers, genital ulcers and anterior uveitis
behcets
HLA B51
behcets
behcets pathergy test
puncture site following needle prick becomes inflamed with small pustule forming
bisphosphonates MOA
inhibit osteoclasts by reducing recruitment and promoting apoptosis
bisphosphonates adverse effects
oesophageal reactions
osteonecrosis of the jaw
> risk atypical stress fractures
acute phase response
hypocalcaemia
important check before starting bisphosphonates
Hypocalcemia/vitamin D deficiency should be corrected before
benign ‘overgrowth’ of bone, most typically occuring on the skull
osteoma
cartilage-capped bony projection on the external surface of a bone
osteochondroma
X-ray shows a ‘double bubble’ or ‘soap bubble’ appearance
giant cell tumour
occurs most frequently in the metaphyseal region of long bones prior to epiphyseal closure
codman triangle and sunburst appearance
Rb gene
osteosarcoma
small round blue cell tumour
onion skin appearance
ewings sarcoma
malignant tumour of cartilage
chondrosarcoma
CFS mx
specialist service
energy mx
physical activity and exercise
CBT
denosumab MOA
human monoclonal antibody that prevents the development of osteoclasts by inhibiting RANKL
prevention of skeletal-related events (i.e. pathological fractures)
denosumab